CJC-1295 (without DAC) and Trenbolone Interaction

Monitor
Mechanism-based 51% confidence

CJC-1295 (without DAC) and Trenbolone have an interaction requiring monitoring for interaction with 51% confidence. Both CJC-1295 (without DAC) and Trenbolone can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Trenbolone

19-Nor Anabolic-Androgenic Steroid | Potent Recomposition Agent

Trenbolone binds to the androgen receptor with approximately three to five times the affinity of testosterone, making it one of the strongest known AR agonists among anabolic steroids. This exceptional binding affinity drives potent activation of AR-dependent gene transcription, resulting in dramatically enhanced nitrogen retention, protein synthesis, and satellite cell proliferation in skeletal muscle.

Half-life: ~3 days (acetate) Typical dose: 200-400 mg/week anabolic
androgen receptoraromataseigf1ngf androgenicblood pressure raisingcarcinogenic riskcardiotoxic
View full profile

Combined Organ Load

Gonads
moderate
Heart
low
GI Tract
low
Pituitary
low
Liver
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), Trenbolone). Monitor accordingly.
2x 2 estrogenic compounds (CJC-1295 (without DAC), Trenbolone). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Trenbolone). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Trenbolone?

Yes, but with caution. Both CJC-1295 (without DAC) and Trenbolone can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is CJC-1295 (without DAC) and Trenbolone safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Trenbolone?

Both CJC-1295 (without DAC) and Trenbolone can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Trenbolone?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Trenbolone has a half-life of ~3 days (acetate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Trenbolone

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.